Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Transpl Int. 2023 Jan 5:35:11073. doi: 10.3389/ti.2022.11073. eCollection 2022.

Marina Lopez-Martinez^{1

2}, Irina Torres^{1

2}, Sheila Bermejo^{1

2}, Francesc Moreso^{1

2}, Clara Garcia-Carro^{3

4}, Ander Vergara^{1

2}, Natalia Ramos^{1

2}, Manel Perello^{1

2}, Alejandra Gabaldon^{2

5}, M Antonieta Azancot^{1

2}, Monica Bolufer^{1

2}, Nestor Toapanta^{1

2}, Oriol Bestard^{1

2}, Irene Agraz-Pamplona^{1

2}, Maria Jose Soler^{1

2}

¹ Department of Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain.
² Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Vall d'Hebron University Hospital, Barcelona, Spain.
³ Department of Nephrology, San Carlos Clinical University Hospital, Madrid, Spain.
⁴ Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), San Carlos Clinical University Hospital, Madrid, Spain.
⁵ Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.

Abstract

[This corrects the article DOI: 10.3389/ti.2022.10693.].

Keywords: CKD progression; IgA nephropathy; IgAN recurrence in transplant kidney; TRF-budesonide; proteinuria reduction.